What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?
Clémence Lacroix(Inserm), Olivier Blin(Inserm), Frank Rouby(Inserm), Arnaud Zalta(Inserm), Laurence Attolini(Inserm), Joëlle Micallef(Institut de Neurosciences des Systèmes), Romain Guilhaumou(Hôpital de la Timone), Élisabeth Jouve(Inserm), Isabelle Alleman-Brimault(Inserm), Catherine Cassé‐Perrot(Inserm)
Cited by 16
Related Papers
Multicenter Prospective Study of Children With Sickle Cell Disease: Radiographic and Psychometric Correlation
|Journal of Child Neurology|2000|244
Use of proton pump inhibitors in adults in France: a nationwide drug utilization study
|European Journal of Clinical Pharmacology|2019|130
French consensus regarding precautions during tracheostomy and post-tracheostomy care in the context of COVID-19 pandemic
|European Annals of Otorhinolaryngology Head and Neck Diseases|2020|76
Serious central nervous system side effects of cephalosporins: A national analysis of serious reports registered in the French Pharmacovigilance Database
|Journal of the Neurological Sciences|2019|60
Artificial Intelligence for Unstructured Healthcare Data: Application to Coding of Patient Reporting of Adverse Drug Reactions
|Clinical Pharmacology & Therapeutics|2021|48